From: Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis

N = 207
| |
---|---|

Age, years, mean (±SD) | 39.5 ± 13.2 |

Female sex, n (%)
| 174 (84.1) |

Hypertension, n (%)
| 100 (48.3) |

Use of antihypertensive drugs, n (%)
| 100 (48.3) |

Systolic BP, mmHg, mean (±SD) | 129.3 ± 16.1 |

Diastolic BP, mmHg, mean (±SD) | 75.6 ± 12.6 |

Diabetes mellitus, n (%)
| 19 (9.2) |

Smoking, n (%)
| 18 (8.7) |

Total cholesterol, mg/dl, mean (±SD) | 180.8 ± 41.0 |

Triglycerides, mg/dl, mean (±SD) | 112.6 ± 66.4 |

HDL cholesterol, mg/dl, mean (±SD) | 56.1 ± 17.0 |

LDL cholesterol, mg/dl, mean (±SD) | 102.2 ± 32.7 |

Framingham risk score, %, median (IQR)^{a}
| 4.1 (2.5–8.0) |

BMI, kg/m^{2}, mean (±SD)
| 22.5 ± 3.1 |

Hemoglobin, g/dl, mean (± SD) | 12.3 ± 1.5 |

Anemia, n (%)
| 84 (40.6) |

ESR, mm/h, median (IQR) | 40.0 (20.0–67.0) |

CRP, mg/l, median (IQR) | 4.0 (1.0–22.0) |

Type of vascular involvement, n (%)
| |

I | 48 (23.2) |

IIA | 23 (11.1) |

IIB | 36 (17.4) |

III | 8 (3.9) |

IV | 11 (5.3) |

V | 81 (39.1) |

Pulmonary artery involvement, n (%)
| 16 (7.7) |

Aortic regurgitation, n (%)
| 61 (29.5) |

Use of glucocorticoids, n (%)
| |

None-to-low dose | 85 (41.1) |

Medium-to-high dose | 122 (58.9) |

Use of MTX, n (%)
| 126 (60.9) |

Use of AZA, n (%)
| 38 (18.4) |

Use of aspirin, n (%)
| 123 (59.4) |

Use of statins, n (%)
| 123 (59.4) |

Cardiovascular events, n (%)
| 41 (19.8) |

Coronary arterial events | 23 (11.1) |

Cerebrovascular events | 15 (7.2) |

Congestive heart failure | 3 (1.4) |